Zepbound
Tirzepatide with Canada's weight-management label, approved in May 2025.
$435–550/mo retail
with LillyConnect copay card: from $25/mo
Overview
Zepbound is Eli Lilly's tirzepatide product carrying a chronic-weight-management label, approved by Health Canada in May 2025. It is the same molecule as Mounjaro, dosed and labelled for weight rather than diabetes — the tirzepatide equivalent of the Ozempic-versus-Wegovy split on the semaglutide side.
At retail, Zepbound runs about $435 to $550 a month depending on dose. Because it is a weight-management drug, no provincial public plan covers it. The standout cost lever is the LillyConnect copay card, which can bring the cost down to as little as a $25 copay — but only if you have private insurance. If you are uninsured or on a public plan, the copay card does not apply, and you would pay retail.
That insurance-gated pricing makes Zepbound one of the clearer cases where your coverage situation, not just the drug, determines what you actually pay.
How it works
Zepbound contains tirzepatide, a dual GIP and GLP-1 receptor agonist. It reduces appetite and slows stomach emptying, and is dosed for chronic weight management. As always, dose selection is a prescriber's decision and outside the scope of this page beyond the label-level frequency.
How it's taken
Zepbound is a once-weekly subcutaneous injection, taken on the same day each week with or without food.
Coverage and what you'll pay
No provincial public plan covers Zepbound, because Canadian public plans cover GLP-1-class drugs only for diabetes. Private employer plans are the route to coverage, and only about 31% of them include weight-loss GLP-1s. If your private plan does cover it, the LillyConnect copay card layered on top can reduce your share to as little as $25.
Without private insurance, expect to pay the full $435 to $550 a month, since the copay card is explicitly limited to privately insured patients. There is no generic tirzepatide, so unlike semaglutide there is no cheaper interchangeable version to fall back on.
Common side effects
GLP-1 side effects are usually digestive and often ease over time. This is not a complete list — read the product monograph and speak with a pharmacist or physician.
- •Nausea, common when starting
- •Diarrhea or vomiting
- •Constipation
- •Reduced appetite
- •Fatigue
- •Injection-site reactions
What Zepbound costs, by source
Monthly prices in Canadian dollars, last verified July 2026. Ranges reflect dose and dispensing-fee variation.
Zepbound — lowest to highest monthly price
Each marker is a source. The list below carries the full detail.
- Retail pharmacies$435–550/mo
- LillyConnect copay cardsavings card$25–435/mo
| Source | Monthly (CAD) | What's included | Verified |
|---|---|---|---|
| LillyConnect copay cardManufacturer program | $25–435 | As low as a $25 copay WITH private insurance only, through the LillyConnect copay card. Not available if you are uninsured or on a public plan. | 2026-07 |
| Retail pharmaciesPharmacy | $435–550 | Zepbound (tirzepatide), Health Canada approved for weight management in May 2025. Cost rises with dose. | 2026-07 |
See the full price database for every drug and source side by side.
Ways to pay less
Manufacturer savings cards and patient-support programs can cut the out-of-pocket cost sharply — but eligibility varies, and terms change. Confirm details on the official manufacturer page before you count on any of these. For the full picture — generic-vs-brand math, tax credits, and insurance appeals — see our ways to pay less navigator.
LillyConnect copay card
Can reduce the out-of-pocket copay for Zepbound to as little as $25 per month.
Eligibility: Requires private insurance; not available to uninsured or publicly insured patients. Terms vary and can change. Confirm on the official page.
Official program page →Availability in Canada
- •Available at Canadian pharmacies since Health Canada approval in May 2025.
- •Not covered by any provincial public plan (weight-loss indication).
- •LillyConnect copay card can lower cost to as little as $25 — with private insurance only.
- •No generic tirzepatide exists.
Frequently asked
- What's the difference between Zepbound and Mounjaro?
- Both are tirzepatide. Mounjaro is labelled for type 2 diabetes; Zepbound is labelled for chronic weight management and was approved in Canada in May 2025. The molecule is the same; the indication, and therefore coverage, differs.
- Can I really get Zepbound for $25?
- Only if you have private insurance. The LillyConnect copay card can reduce your copay to as little as $25, but it does not apply to uninsured or publicly insured patients, who would pay retail of roughly $435 to $550 a month.
- Is Zepbound covered by provincial plans?
- No. Canadian public drug plans cover GLP-1-class medications only for diabetes, not weight management, so Zepbound is not publicly covered anywhere in Canada.
Watching the pipeline?
Next-generation drugs like retatrutide and orforglipron are still investigational and not approved in Canada. We'll email you the moment that changes — nothing before. Read the full watch page.